Tipiramato [Spanish] en es it fr

Categorie

Tipiramato [Spanish] Les marques, Tipiramato [Spanish] Analogs

Tipiramato [Spanish] Les marques melange

  • No information avaliable
  • Tipiramato [Spanish] Formule chimique

    C12H21NO8S

    Tipiramato [Spanish] RX lien

    http://www.rxlist.com/cgi/generic2/topiram.htm

    Tipiramato [Spanish] FDA fiche

    Tipiramato_[Spanish] FDA

    Tipiramato [Spanish] msds (fiche de securite des materiaux)

    Tipiramato_[Spanish] MSDS

    Tipiramato [Spanish] Synthese de reference

    Aucune information disponible

    Tipiramato [Spanish] Poids moleculaire

    339.363 g/mol

    Tipiramato [Spanish] Point de fusion

    No information avaliable

    Tipiramato [Spanish] H2O Solubilite

    9,8 mg / ml

    Tipiramato [Spanish] Etat

    Solid

    Tipiramato [Spanish] LogP

    0.712

    Tipiramato [Spanish] Formes pharmaceutiques

    Capsule (15 et 25 mg saupoudrez capsules); Tablet (25, 50, 100 et 200 mg)

    Tipiramato [Spanish] Indication

    Utilisé pour le traitement et le contrôle des crises partielles et graves crises tonico-cloniques (grand mal) saisies et aussi pour la prévention des migraines. Chez les enfants, il est également utilisé pour le traitement du syndrome de Lennox-Gastaut.

    Tipiramato [Spanish] Pharmacologie

    Topiramate est un anticonvulsivant indiqué dans le traitement de l'épilepsie et la migraine. Le topiramate améliore canaux chlorure GABA-activé. En outre, le topiramate inhibe la neurotransmission excitatrice, par des actions sur kaïnate et récepteurs AMPA. Il est évident que le topiramate a un effet spécifique sur les récepteurs kaïnate GluR5. Il est également un inhibiteur de l'anhydrase carbonique, notamment les sous-types II et IV, mais cette action est faible et peu susceptible d'être liés à ses actions anticonvulsivant, mais peut expliquer le mauvais goût et le développement de calculs rénaux vu pendant le traitement. Son effet possible comme un stabilisateur de l'humeur semble se produire avant que des qualités anticonvulsivant à des doses plus faibles. Le topiramate inhibe l'électrochoc maximal et pentylènetétrazol convulsions induites ainsi que partielle et secundarily généralisées tonico-cloniques dans le modèle de l'embrasement, les conclusions predective d'un large spectre d'activités anticonvulsivants cliniquement.

    Tipiramato [Spanish] Absorption

    Rapide avec pleak concentrations plasmatiques survenant après 2 heures et une biodisponibilité de 80%.

    Tipiramato [Spanish] Toxicite

    Les symptômes de surdose comprennent des douleurs abdominales, agitation, vision floue, convulsions, dépression, vertiges, vision double, somnolence, l'incoordination, une altération de l'activité mentale, une pression artérielle basse, diminution de la conscience, une diarrhée sévère, la morosité, et les problèmes d'élocution.

    Tipiramato [Spanish] Information pour les patients

    Topamax is an antiepileptic drug, prescribed to control both the mild attacks known as partial seizures and the severe tonic-clonic convulsions known as grand mal seizures. It is typically added to the treatment regimen when other drugs fail to fully control a patient's attacks.

    Topamax is also prescribed for the prevention of migraine headaches (also known as prophylactic treatment). However, due to a lack of studies, it's not known whether the drug can treat acute migraine attacks.

    Because Topamax sometimes causes confusion, dizziness, fatigue, and problems with coordination and concentration, you should not drive, operate machinery, or participate in any hazardous activity that requires full mental alertness until you are certain how the drug affects you.

    Topamax has been known to cause a potentially serious condition known as metabolic acidosis (an increase of acid in the blood). In children, chronic metabolic acidosis may affect growth or cause rickets (a softening or weakness of the bones that can lead to bone deformities). Contact your doctor immediately if you experience symptoms of metabolic acidosis such as rapid breathing, an irregular heartbeat, confusion, lethargy, fatigue, or loss of appetite. Your doctor will decide if you should discontinue taking Topamax. Do not abruptly stop taking Topamax on your own; your doctor will gradually taper the dosage to avoid an increase in seizures.

    Topamax has been known to trigger severe nearsightedness along with increased pressure inside the eye. The problem usually occurs within 1 month of starting treatment. If you develop blurred vision or eye pain, call your doctor immediately. Discontinuation of the drug may be necessary to prevent permanent vision loss.

    In children with chronic diarrhea or untreated kidney disorders, use of Topamax may lead to rickets and reduced growth rates.

    Tell your doctor if you have kidney problems or if you are on hemodialysis; your dosage of Topamax may need adjustment. Elderly patients in particular may experience reduced kidney function when taking Topamax. Also make sure the doctor is aware of any liver disorder you may have. Topamax must be used cautiously by individuals with impaired liver function.

    Anyone using Topamax, particularly children, should be carefully monitored by their doctor for signs of increased body temperature or decreased sweating, especially during hot weather.

    In rare instances, suicide attempts have been reported in people taking Topamax.

    Tipiramato [Spanish] Organismes affectes

    Les humains et autres mammifères